je.st
news
Tag: new
TETRA Technologies, Inc. (TTI) - Oil & Gas - Deals and Alliances Profile - New Market Study Published
2015-06-01 04:44:49| Chemicals - Topix.net
It offers a wide range of services including production well testing, compression-based production enhancement, decommissioning, water management, cooling, after-frac flow back, and selected offshore services, among others. The company's operations are composed of five reporting segments organized into three divisions, namely, Fluids, Production Enhancement, and Offshore.
Tags: new
profile
market
study
Lean years behind it, Eli Lilly sees growth in new drugs
2015-05-31 15:39:30| Food - Topix.net
Lean years behind it, Eli Lilly sees growth in new drugs "We had to find our true grit," CEO John Lechleiter says of past five years Check out this story on IndyStar.com: http://indy.st/1HDLXCO The loss of 60 percent of its revenue from patent expirations from 2011-2014 put Eli Lilly and Co. at risk.
Lean years behind it, Eli Lilly sees growth in new drugs
2015-05-31 14:26:47| Agriculture - Topix.net
Lean years behind it, Eli Lilly sees growth in new drugs "We had to find our true grit," CEO John Lechleiter says of past five years Check out this story on IndyStar.com: http://indy.st/1HDLXCO The loss of 60 percent of its revenue from patent expirations from 2011-2014 put Eli Lilly and Co. at risk.
Latest on flooding: Rain-weary Houston gets a new storm
2015-05-31 03:11:35| Energy - Topix.net
The city's primary electric provider, CenterPoint Energy, reported more than 18,000 customers without power as the late afternoon storms moved through. Outages primarily have been immediately to the west of downtown Houston and in the far north and northeast sections of the city.
Tags: new
latest
houston
storm
First Study Evaluating DNA Mismatch Repair as Genetic Guide for Immunotherapy Treatment with Mercks KEYTRUDA (pembrolizumab) Presented at 2015 ASCO Annual Meeting and Published in the New England Journal of Medicine
2015-05-29 20:05:00| Merck.com - Product News
Dateline City: KENILWORTH, N.J. Early Findings Show DNA Mismatch Repair-Deficient Colorectal and Other Tumors Highly Responsive to Checkpoint Blockade with Anti-PD-1 Therapy Merck Plans to Initiate Phase 2 Registrational Study with KEYTRUDA (KEYNOTE-164) to Evaluate MMR-Deficiency in Colorectal Cancer KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced results from the first study evaluating the correlation of benefit with an immunotherapy based on DNA mismatch repair (MMR) deficiency, a well-established form of genetic instability in many cancers characterized by the loss of function of the MMR pathway. Language: English Contact: MerckMedia:Pamela Eisele, 267-664-0282Claire Mulhearn, 908-200-1889orInvestors:Joseph Romanelli, 908-740-1986Justin Holko, 908-740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Sites : [208] [209] [210] [211] [212] [213] [214] [215] [216] [217] [218] [219] [220] [221] [222] [223] [224] [225] [226] [227] next »